| Today’s Big NewsJun 24, 2025 |
| By Zoey Becker The company noted high rates of discontinuation due to gastrointestinal events, such as vomiting, in fixed-dose arms of its phase 2 trial. |
|
|
|
By James Waldron Rivus’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the drug's obesity potential. |
By Nick Paul Taylor MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron. |
By James Waldron Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market. |
|
Immune cell engagers are opening new avenues in immuno-oncology. Discover how single-cell analysis is enabling smarter, faster ICE discovery. Watch now
|
|
By Nick Paul Taylor Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. The biotech reported a phase 2 win for rezpegaldesleukin in atopic dermatitis, sending its stock up 119% despite the data falling short of the bar set by Regeneron and Sanofi’s Dupixent. |
By James Waldron Stuart Therapeutics’ dry eye disease drug has failed to demonstrate it can increase tear production in a phase 3 test. |
By Angus Liu While three Big Pharma companies have yet to successfully crack the ROS1 lung cancer market, young biotech Nuvalent believes competitive pivotal data from its investigational drug are paving the way to a quick FDA filing and, eventually, a chance at a major opportunity. |
By Nick Paul Taylor BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. The biotech linked its challenger to bigger reductions in blood sugar than Novo Nordisk’s semaglutide, giving momentum as it barrels toward a readout from a head-to-head trial against Eli Lilly’s tirzepatide. |
By Zoey Becker With a goal of boosting its life sciences economy into the top three of the global rankings by 2035, the U.K. government is laying out six specific areas of focus to bolster its growth in the industry. |
By Eric Sagonowsky Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows an intense period of leadership turnover at the agency isn't over. |
By Angus Liu Sen. Bill Cassidy, M.D., R-La., has come out critical of Robert F. Kennedy Jr.’s picks for the CDC’s vaccine advisory panel, calling for the committee’s upcoming meeting to be postponed. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now.
|
|
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
